TrialThe Journal of pharmacology and experimental therapeutics2024

Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.

Rachel Luba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.